Prevail Partners

Coologics is a clinical-stage medical device company specializing in drug-free solutions for vaginal yeast infections. Their primary product is a device that combines physical and mechanical interactions with the vaginal wall, time-controlled cooling to treat infections, alleviate symptoms, restore the vaginal microbiome and pH, and disrupt biofilms.

Triple Hair is a company focused on developing solutions for thinning hair and hair loss, specifically targeting conditions such as alopecia. The company offers a triple combination therapy that utilizes synergistic effectiveness to promote hair growth in men. This innovative approach aims to prevent hair loss while enhancing hair thickness and pigmentation. Through its topical hair growth therapies, Triple Hair addresses the needs of individuals seeking to improve their hair health and appearance.

Stamford Pharmaceuticals focuses on developing innovative immunotherapy treatments for primary, recurrent, and metastatic cancers. It employs various technologies, including viral vectors and affinity agents, to deliver biological therapies, aiming to provide advanced treatment options for patients with cancer.

HemoGenyx LLC is a biopharmaceutical company based in Brooklyn, New York, that specializes in developing innovative treatments for blood diseases, including leukemia and lymphoma. Established in 2013, the company focuses on harnessing adult hemogenic endothelial cells to produce cancer-free hematopoietic stem cells for transplantation. This approach aims to enhance the effectiveness of bone marrow transplants while eliminating the reliance on donor sources. By leveraging this unique cellular technology, HemoGenyx seeks to significantly improve patient outcomes in the treatment of blood cancers.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on immuno-oncology and the development of innovative therapies for cancer management. The company’s lead candidate, Bria-IMT, is a targeted cell-based immunotherapy derived from a breast cancer cell line, currently undergoing a Phase I/IIa clinical trial in combination with immune checkpoint inhibitors for advanced breast cancer. BriaCell has achieved positive proof-of-concept for Bria-IMT in this patient population. Additionally, the company is developing Bria-OTS, an off-the-shelf personalized immunotherapy aimed at advanced breast cancer, as well as BriaDx, a diagnostic test. BriaCell Therapeutics is headquartered in West Vancouver, Canada, and collaborates with the National Cancer Institute to advance its research initiatives.

PolyPhotonix is a bio-photonic company focused on research, development, and manufacture of non-invasive light therapy medical devices. It designs and produces home care products that apply light therapy to treat eye diseases such as macular degeneration and diabetic retinopathy. The company collaborates with designers and key customers to advance products from concept through manufacturing and is based at the National Printable Electronics Centre.